Juno Therapeutics Announces Pricing of Initial Public Offering

SEATTLE--()--Juno Therapeutics, Inc. today announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share. In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any. Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014. The offering is expected to close on December 23, 2014, subject to customary closing conditions.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.

The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by calling toll-free (866) 471-2526, or by e-mailing prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on December 18, 2014. Copies of the registration statement, as amended, can be accessed through the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Juno

Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Contacts

W2O Group
Investor Relations:
David Walsey, 858-617-0772
dwalsey@w2ogroup.com
or
Media:
Andreas Marathovouniotis, 212-301-7174
amarathis@w2ogroup.com

Contacts

W2O Group
Investor Relations:
David Walsey, 858-617-0772
dwalsey@w2ogroup.com
or
Media:
Andreas Marathovouniotis, 212-301-7174
amarathis@w2ogroup.com